Moderna Swings to Q3 Profit, Raises Outlook on Strong COVID Vaccine Demand
OverviewOutlookResult DriversCompany press release:Key DetailsReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automati…
Story updates
12:16:32 PM UTC
SquawkNews
By Jaimy LeeThe company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026Moderna's top-selling product is still Spikevax, its mRNA-based COVID-19 vaccine. (Photo by JOSEPH PREZIOSO/AFP via Getty Images)Moderna, which is best known for advancing th…
12:22:23 PM UTC
SquawkNews
By Connor HartModerna raised its full-year outlook as it swung to a profit and logged higher revenue in the recent quarter, boosted in part by stabilizing demand for its Covid-19 vaccine.Shares were up 9.6% to $264.79 in premarket trading.The biopharmaceutical company said Friday it now expects tot…
OverviewOutlookResult DriversCompany press release:Key DetailsReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automati…